You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Request a contact

Stay informed

Live Chat

Go to Close Top

Indication 1

Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

Dosage 1

Bexsero is available as a white opalescent liquid suspension for injection in a pre-filled syringe and comes as a 0.5 ml dose.

Bexsero offers several schedule options with flexible dosing intervals, making it simple to fit with routine vaccination visits. 1

Bexsero Overview

The use of this vaccine should be in line with official recommendations.

Coadministration:

Bexsero can be given concomitantly with any of the following vaccine antigens, either as monovalent or as combination vaccines 1:

— Meningococcal groups A, C, W, Y conjugate

— Diphtheria, tetanus, acellular pertussis, inactivated polio

— Haemophilus influenzae type b

— Hepatitis B

— Heptavalent pneumococcal conjugate

— Measles, mumps, rubella

— Varicella

Storage and stability 1

  • Shelf life: 3 years
  • Store in a refrigerator (2°C–8°C)
  • Do not freeze
  • Store in the original package in order to protect from light
  • Upon storage, a fine off-white deposit may be observed in the prefilled syringe containing the suspension
  • Before use, the pre-filled syringe should be well shaken in order to form a homogeneous suspension. 

View Resources

References:

  1. Bexsero Summary of Product Characteristics. Available from:https://www.medicines.ie/medicines/bexsero-suspension-for-injection-in-pre-filled-syringe-31445/ Last accessed – August 2020
  2. HSE Immunisation Guidelines. Available from: https://www.hse.ie/eng/health/immunisation/hcpinfo/guidelines/chapter13.pdf, accessed: August 2020

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Bexsero is a registered trademark of the GlaxoSmithKline Group of Companies